Publications by authors named "P-R Burgel"

Claim this Profile
E
European Respiratory Society clinical practice guideline for the management of adult bronchiectasis.
James D Chalmers, Charles S Haworth, Patrick Flume, Merete B Long, Pierre-Régis Burgel

Eur Respir J· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.
Iwona Pranke, Valeria Capurro, Benoit Chevalier, Emanuela Pesce, Valeria Tomati, Pierre-Régis Burgel

Front Pharmacol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.
Barry J Plant, Gisli G Einarsson, Kevin F Deasy, Darren Dahly, Pradeep K Singh, Pierre-Régis Burgel

Eur Respir J· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validity of the Chronic Airways Assessment Test (CAAT) in asthma, asthma+COPD and COPD in NOVELTY.
Paul W Jones, Erin L Tomaszewski, Laura Belton, Pierre-Régis Burgel, Rod Hughes

ERJ Open Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CFTR modulators and pregnancy outcomes: Early findings from a nationwide cohort study.
Laurent Chouchana, Mathis Collier, Clémence Martin, Pierre-Régis Burgel, Jean-Marc Treluyer

J Cyst Fibros· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance for chest-CT in children and adults with cystic fibrosis: A European perspective.
Michael Fayon, Kate Hill, Michael Waldron, Barbara Messore, Luca Riberi, Pierre-Régis Burgel

Respir Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis.
Paulette Magnas, Sihem Benaboud, Jennifer Da Silva, Clémence Martin, Reem Kanaan, Pierre-Régis Burgel

Eur Respir J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aspergillus Serologic Findings and Clinical Outcomes in Patients With Bronchiectasis: Data From the European Bronchiectasis Registry.
Jennifer Pollock, Pieter C Goeminne, Stefano Aliberti, Eva Polverino, Megan L Crichton, Pierre-Régis Burgel

Chest· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of CFTR modulators in patients with interstitial lung disease caused by ABCA3 transporter deficiency.
Mathilde Le Brun, Nadia Nathan, Camille Louvrier, Marie Legendre, Severine Feuillet, Pierre-Régis Burgel

ERJ Open Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA.
Elizabeth A Cromwell, Josh S Ostrenga, Don B Sanders, Wayne Morgan, Carlo Castellani, Pierre-Regis Burgel

Eur Respir J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!
Guillaume Chassagnon, Pierre-Régis Burgel

Eur Respir J· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftolozane/Tazobactam for the Treatment of Adults With Cystic Fibrosis: Results From a French Prospective Cohort Study.
Pierre-Régis Burgel, Xavier Bourge, Carole Mackosso, Francois Parquin

Open Forum Infect Dis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brensocatib in non-cystic fibrosis bronchiectasis: ASPEN protocol and baseline characteristics.
James D Chalmers, Pierre-Régis Burgel, Charles L Daley, Anthony De Soyza, Charles S Haworth

ERJ Open Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New drugs, new challenges in cystic fibrosis care.
Isabelle Fajac, Pierre-Régis Burgel, Clémence Martin

Eur Respir Rev· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
Arietta Spinou, Beatriz Hererro-Cortina, Stefano Aliberti, Pieter C Goeminne, Eva Polverino, Pierre Regis Burgel

Eur Respir J· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationships between symptoms and lung function in asthma and/or chronic obstructive pulmonary disease in a real-life setting: the NOVEL observational longiTudinal studY.
Alberto Papi, Rod Hughes, Ricardo Del Olmo, Alvar Agusti, Bradley E Chipps, Pierre-Régis Burgel

Ther Adv Respir Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
Stefano Aliberti, Felix C Ringshausen, Raja Dhar, Charles S Haworth, Michael R Loebinger, Pierre-Regis Burgel

Eur Respir J· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
Paul Cazier, Guillaume Chassagnon, Théo Dhote, Jennifer Da Silva, Reem Kanaan, Pierre-Régis Burgel

Eur Respir J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cystic fibrosis in the era of CFTR modulators: did the neutrophil slip through the cracks?
Véronique Witko-Sarsat, Pierre-Régis Burgel

J Leukoc Biol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
Pierre-Régis Burgel

Eur Respir J· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
complex pulmonary disease patients with limited treatment options.
Stefano Aliberti, Francesco Blasi, Pierre-Régis Burgel, Andrea Calcagno, Andreas Fløe

ERJ Open Res· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare variants: a viewpoint.
Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, Emmanuelle Girodon, Reem Kanaan, Jean Le Bihan

Eur Respir J· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cast no shadow: assessing the disease-modifying effects of elexacaftor/tezacaftor/ivacaftor.
Peter J Barry, Pierre-Régis Burgel

Eur Respir J· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
Elise Dreano, Pierre Régis Burgel, Aurelie Hatton, Naim Bouazza, Benoit Chevalier

Eur Respir J· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' acceptance of outcome and experience measurements during hospitalisation for COPD exacerbations: a CICERO Clinical Research Collaboration-European Lung Foundation online patient survey.
Iwein Gyselinck, Sanjay Ramakrishnan, Kristina Vermeersch, Andreas Halner, Hendrik Pott, Pierre-Régis Burgel

ERJ Open Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis